Clinical outcome of radiotherapy for primary tumors in stage Ⅳ non-small cell lung cancer complicated with malignant pleural effusion
Wei Tianyu, Ma Zhu, Chen Xiaxia, Li Xiaoyang, Ouyang Weiwei, Su Shengfa, Li Qingsong, Geng Yichao, Yang Wengang, Hu Yinxiang, Li Huiqin, Lu Bing
Department of Oncology, Guizhou Medical University/Department of Oncology, Affiliated Hospital of Guizhou Medical University/Guizhou Cancer Hospital, Guiyang 550004, China
Abstract：Objective To retrospectively analyze the clinical efficacy and safety of three-dimensional radiotherapy for the primary tumors in patients with stage Ⅳ non-small cell lung cancer complicated with malignant pleural effusion (MPE-NSCLC). Methods A total of 198 patients who were initially pathologically diagnosed with MPE-NSCLC from January 2007 to April 2018 were enrolled and divided into the untreated group (n=45), drug group (n=57) and radiotherapy group (n=96), respectively. The short-term efficacy, overall survival (OS) and adverse events in the drug and radiotherapy groups were analyzed. The OS rate was analyzed by Kaplan-Meier method and log-rank test. Clinical prognosis was evaluated by multivariate Cox's regression model. Results In the radiotherapy group, the objective response rate and non-response rate was 54% and 46%, significantly better than 25% and 75% in the drug group (P=0.007). In the radiotherapy group, the 1-, 2-, 3-, 5-year OS and median survival was 47%, 18%, 6%, 1% and 12 months, remarkably higher than 15%, 3%, 2%, 0% and 5 months in the drug group, respectively (all P<0.001). Multivariate Cox's regression analysis showed that radiotherapy for the primary tumors was an independent prognostic factor to prolong the OS (P<0.001). Radiotherapy at a dose of ≥63Gy and 4-6 cycles of chemotherapy tended to prolong the OS (P=0.063 and 0.071). The OS of patients with EGFR mutation receiving radiotherapy combined with molecular target therapy was significantly better than that of those with unknown EGFR status treated with radiotherapy and chemotherapy (P=0.007). Addition of radiotherapy for the primary tumors did not significantly increase the incidence of adverse events (P>0.05). Conclusion Addition of three-dimensional radiotherapy for the primary tumors in MPE-NSCLC patients may prolong the OS and yield tolerable adverse events.
Wei Tianyu,Ma Zhu,Chen Xiaxia et al. Clinical outcome of radiotherapy for primary tumors in stage Ⅳ non-small cell lung cancer complicated with malignant pleural effusion[J]. Chinese Journal of Radiation Oncology, 2020, 29(7): 523-528.
[1] Porcel JM, Gasol A, Bielsa S, et al. Clinical features and survival of lung cancer patients with pleural effusions[J]. Respirology, 2015, 20(3):654-659. DOI:10.1111/resp.12496. [2] Gonzalez AV, Bezwada V, Beamis JF Jr. Lung injury following thoracoscopic:experience of a single North American center[J]. Chest, 2010, 137(6):1375-1381. DOI:10.1378/chest.09-2020. [3] Clive AO, Kahan BC, Hooper CE, et al. Predicting survival in malignant pleural effusion:Development and validation of the LENT prognostic score[J]. Thorax, 2014, 69(12):1098-1104. DOI:10.1136/thoraxjnl-2014-205285. [4] Postmus PE, Brambilla E, Chansky K, et al. The IASLC Lung Cancer Staging Project:proposals for revision of the M descriptors in the forthcorning (seventh) edition of the TNM classification of lung cancer[J]. Thorac Oncol, 2007, 2(8):686-693. DOI:10.1097/JTO.0b013e31811f4703. [5] International Association for the Study of Lung Cancer. Staging manual in thoracic oncology[M]. NY, 2009. [6] Lazzari C, Karachaliou N, Bulotta A, et al. Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer:is this the beginning of the end for cancer?[J]. Ther Adv Med Oncol, 2018, 4. DOI:10:175883591876209. [7] Hanna GG, Illidge T. Radiotherapy and immunotherapy combinations in non-small cell lung cancer:a promising future?[J]. Clin Oncol, 2016, 28(11):726-731. DOI:10.1016/j.clon.2016.07.014. [8] Simone ICB, Burri SH, Heinzerling JH. Novel radiotherapy approaches for lung cancer:combining radiation therapy with targeted and immunotherapies[J]. Transl Lung Cancer Res, 2015, 4(5):545. DOI:10.3978/j.issn.2218-6751.2015.10.05. [9] Su SF, Li T, Lu B, et al. Three-dimensional radiation therapy to the primary tumor with concurrent chemotherapy in patients with stage Ⅳ non-small cell lung cancer:results of a multicenter phase 2 study from PPRA-RTOG, China[J]. Int J Radiat Oncol Biol Phys, 2015, 93(4):769-777. DOI:10.1016/j.ijrobp.2015.08.012. [10] El-Kolaly RM, Abo-Elnasr M, El-Guindy D. Outcome of pleurodesis using different agents in management of malignant pleural effusion[J]. Egyp J Chest Dis Tuber, 2016, 65(2):435-440. DOI:10.1016/j.ejcdt.2015.12.017. [11] Yang J, Lee OJ, Son SM, et al. EGFR mutation status in lung adenocarcinoma-associated malignant pleural effusion and efficacy of EGFR tyrosine kinase inhibitors[J]. Cancer Res Treat, 2018, 50(3):908-916. DOI:10.4143/crt.2017.378. [12] Masago K, Fujimoto D, Fujita S, et al. Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer[J]. Mol Clin Oncol, 2014, 3(2):415-419. DOI:10.3892/mco.2014.457. [13] Yamaguchi M, Ichinose Y, Shimamatsu S, et al. Preoperative concurrent chemoradiotherapy followed by extrapleural pneumonectomy for patients with non-small cell lung cancer with malignant pleural effusions and/or pleural nodles:Ten-year results of aprematurely terminated single institute phase Ⅱ trial[J]. Surg Oncol, 2015, 24(2):78-83. DOI:10.1016/j.suronc.2015.02.004. [14] Ouyang WW, Su SF, Hu YX, et al. Radiation dose and survival of patients with stage ⅠV non-small cell lung cancer undergoing concurrent chemotherapy and thoracic three-dimensional radiotherapy:reanalysis of the findings of a single-center prospective study[J]. BMC Cancer, 2014, 14(1):491. DOI:10.1186/1471-2407-14-491. [15] Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer:a phase 2 randomized clinical trial[J]. JAMA Oncol, 2017, 99(5):e173501. DOI:10.1001/jamaoncol.2017.3501. [16] Daniel RG, George RB Jr, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy:a multicentre, randomised, controlled, phase 2 study[J]. Lancet Oncol, 2016, 16(1):1-11. DOI:10.1016/S1470-2045(16)30532-0. [17] Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer:a secondary analysis of the KEYNOTE-001 phase 1 trial[J]. Lancet Oncol, 2017, 18(7):895. DOI:10.1016/ S1470-2045(17)30380-7. [18] Masters GA, Temin S, Azoli CG, et al. Systemic therapy for stage Ⅳ non-smal-cell lung cancer:American society of clinical oncology clinical practice guideline update[J]. J Clin Oncol, 2010, 27(36):3488-515. DOI:10.1200/JCO.2015.62.1342. [19] Lopez-Guerra JL, Gomez D, Zhuang Y, et al. Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis[J]. Int J Radiat Oncol Biol Phys, 2012, 84(1):e61-e67. DOI:10.1016/j.ijrobp.2012.02.054. [20] Koshy M, Malik R, Mahmood U, et al. Comparative effectiveness of aggressive thoracic radiation therapy and concurrent chemoradiation therapy in metastatic lung cancer[J]. Pract Radiat Oncol, 2015, 5(6):274-282. DOI:10.1016/j.prro.2015.07.009. [21] Bentzen M, Skoczylas JZ, Ber J, et al. Quantitative clinical radiobiology of early and late lung reactions[J]. Int J Radiat Biol, 2000, 76(4):453-462. DOI:10.1080/095530000138448.
2020, Vol. 29 
